Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2010

Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases

  • Index Ventures has pledged to provide up to a €10 million (about $14 million) investment in Mind-NRG, a newly incorporated Swiss CNS disease therapeutics firm. The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101, which it claims has disease-modifying potential and can cross the blood-brain barrier by receptor-mediated transport to reach its target. NRG-101 has been acquired from German systems biology firm ProteoSys in return for Mind-NRG equity.

    Funding from Index includes an initial €1.5 million in Series A financing, which will support research at Mind-NRG to generate additional key data on the drug. In the near-term the firm will focus on conducting in vitro and in vivo studies to further explore the peptide’s mechanism of action and its activity in a range of relevant disease models.

    Mind-NRG says it ultimately aims to develop NRG-101 for the treatment of neurological and psychiatric disorders including schizophrenia, Parkinson disease, and Alzheimer disease. Index Ventures partner Michèle Ollier has been appointed as Mind-NRG chairman.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »